Table 5.

Occurrence of Cardio‐ and Cerebrovascular as Well as Other Events During the Longitudinal Follow‐Up in Patients With or Without MA During the ROADMAP Study

	MA No (n=1626)	MA Yes (n=132)	Odds Ratio (95%‐CI)	P Value
Cardio‐/cerebrovascular morbidity and mortality, n (%)	138 (8.5)	21 (15.9)	1.766 (1.029; 3.030)	0.039
Cardio‐/cerebrovascular morbidity, n (%)	138 (8.5)	21 (15.9)	1.766 (1.029; 3.030)	0.039
Cardiovascular morbidity, n (%)	114 (7.0)	17 (12.9)	1.607 (0.887; 2.913)	0.118
Acute coronary syndrome	40 (2.5)	7 (5.3)	1.974 (0.814; 4.784)	0.132
Coronary revascularisation	38 (2.3)	4 (3.0)	0.940 (0.290; 3.046)	0.918
Silent myocardial infarction	4 (0.2)	0 (0.0)	n.a.	n.a.
Congestive heart failure*	11 (0.7)	4 (3.0)	3.168 (0.877; 11.451)	0.079
New onset of atrial fibrillation	36 (2.2)	5 (3.8)	1.837 (0.662; 5.096)	0.243
Peripheral vascular disease*	14 (0.9)	2 (1.5)	1.449 (0.285; 7.359)	0.655
Cerebrovascular morbidity, n (%)	31 (1.9)	5 (3.8)	2.070 (0.729; 5.881)	0.172
Non fatal stroke	23 (1.4)	2 (1.5)	1.389 (0.293; 6.594)	0.679
Transient ischemic attack	9 (0.6)	3 (2.3)	3.389 (0.809; 14.207)	0.091
Cardio‐/cerebrovascular mortality*, n (%)	2 (0.1)	0 (0.0)
Congestive heart failure	1 (0.1)	0 (0.0)	n.a.	n.a.
Fatal stroke	1 (0.1)	0 (0.0)
Non‐CV related mortality, n (%)	7 (0.4)	1 (0.8)	1.098 (0.089; 13.507)	0.942
Not CV related death	5 (0.3)	0 (0.0)	n.a.	n.a.
Death of unknown cause	2 (0.1)	1 (0.8)	4.310 (0.301; 61.702)	0.282
Total mortality, n (%)	9 (0.6)	1 (0.8)	0.838 (0.067; 13.507)	0.891
Other endpoints, n (%)
End stage renal disease	2 (0.1)	0 (0.0)	n.a.	n.a.
New onset diabetic retinopathy	27 (1.7)	4 (3.0)	1.758 (0.551; 5.605)	0.340

CV indicates cardio‐/cerebrovascular events; MA, microalbuminuria; n.a., not applicable; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention.

^*Requiring hospital treatment.

^*No death due to sudden cardiac death, myocardial infarction or during cardiovascular surgery was reported.